Singapore Healthcare REIT Under the Microscope: 3 Good and 3 Red Flags
Parkway Life REIT stands at a crossroads. After 17 years of uninterrupted DPU growth, this healthcare giant faces new challenges that could test its defensive reputation.
Healthcare REITs typically offer stability when markets turn volatile. But recent results show cracks in the armor. While revenue climbed 8.1% in 1H2025, earnings per unit dropped 22% and the stock trades at premium valuations. Singapore investors need clarity on whether this healthcare stalwart remains a reliable income play or if warning signs are flashing red.
This analysis cuts through the noise with three compelling positives, three serious red flags, and a clear verdict on positioning for Singapore portfolios. We examine everything from the transformative France expansion to concerning concentration risks that could derail future returns.
Company Snapshot and Why Now
Parkway Life REIT owns Asia's largest healthcare REIT portfolio valued at S$2.46 billion across 75 properties. The REIT operates three private hospitals in Singapore that generate two-thirds of income, plus nursing homes in Japan and France. Recent results for 1H2025 showed gross revenue rising 8.1% to S$78.3 million, driven by contributions from its December 2024 French acquisition.
Table: Portfolio Overview
This table highlights Parkway Life REIT’s asset footprint. Singapore remains the concentration core, while Japan and France supply income diversity through long-term and master leases.
The market currently prices the REIT at a 70% premium to book value, suggesting investors expect continued growth despite execution challenges. Singapore’s aging population and Japan’s demographic tailwinds support long-term demand, but near-term headwinds include debt maturities and concentration risks.
Table: Valuation and Income Snapshot (September 2025)
Parkway Life REIT trades at a premium with a lower yield and higher earnings multiples than the SREIT average. Defensive debt metrics counterbalance high valuation risk, supporting resilience through market cycles.
